Food and Drug Administration approval of a fifth acellular pertussis vaccine for use among infants and young children--United States, 2002.
On May 14, 2002, the Food and Drug Administration (FDA) approved for use an additional combined diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) (DAPTACEL Aventis Pasteur, Ltd. [Toronto, Ontario]) for the first 4 doses of the diphtheria and tetanus toxoids and pertussis vaccination (DTP) series administered to infants and children aged 6 weeks-6 years (before seventh birthday). DAPTACEL is the fifth acellular pertussis vaccine to be licensed for use among infants and young children in the United States. Of these five, three (Tripedia, Infanrix, and DAPTACEL) are distributed in the United States.
D002675:Child, Preschool; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000008:administration & dosage; D017277:Drug Approval; D006801:Humans; D007223:Infant; D014481:United States; D014486:United States Food and Drug Administration
D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines